If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
New Product Development » New Product Planning
Download FREE Excerpt
18 Info Graphics
22 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The pharmaceutical industry's New Product Planning (NPP) function has become the central conduit for assessing potential therapies as they progress through the three stages of drug development. NPP engages in a series of activities designed to determine the market fit and potential profitability of identified candidates and to prepare for key commercial activities, such as positioning and branding. Two of the critical areas that the NPP function assess are medical affairs and brand strategy.
Best Practices, LLC undertook this benchmarking study to determine which medical affairs and brand activities should be conducted and when for the NPP group. The study identifies the timing of key medical affairs and brand strategy NPP activities in launch & pre-launch. The research also includes chapters on the current state of NPP in the pharma sector and key patterns in the timing of NPP activities.
For this research project, Best Practices, LLC engaged 19 leaders from 15 leading pharmaceutical, biotech, and life sciences companies.
Biopharmaceutical; Pharmaceutical; Medical Device; Biotech; Health Care; Clinical Research; Laboratories; Manufacturing; Consumer Products; Diagnostic
Alkermes; Zydus Cadila; GlaxoSmithKline ; Astellas; Roche; Novartis; Sanofi; Pfizer; Takeda Pharmaceuticals; Cytokinetics; Allergan; Medicago; Bayer; Galderma; Wockhardt